Celcuity Inc. (CELC): Price and Financial Metrics
GET POWR RATINGS... FREE!
CELC Stock Price Chart Interactive Chart >
CELC Price/Volume Stats
| Current price | $15.10 | 52-week high | $33.01 |
| Prev. close | $14.50 | 52-week low | $8.75 |
| Day low | $14.01 | Volume | 26,500 |
| Day high | $15.59 | Avg. volume | 159,157 |
| 50-day MA | $17.63 | Dividend yield | N/A |
| 200-day MA | $20.82 | Market Cap | 225.20M |
Celcuity Inc. (CELC) Company Bio
Celcuity LLC, a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the response rates of cancer patients treated with targeted therapies in the United States. It develops CELx tests to diagnose breast, lung, colon, ovarian, kidney, bladder, and hematological cancers. The company was founded in 2012 and is based in Minneapolis, Minnesota.
Latest CELC News From Around the Web
Below are the latest news stories about Celcuity Inc that investors may wish to consider to help them evaluate CELC as an investment opportunity.
Celcuity Appoints Michael Snitkovsky as VP of Program Management and David Bridge as VP of Quality Assurance and Process DevelopmentMINNEAPOLIS, MN / ACCESSWIRE / November 29, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, today announced the addition of two senior executives to its corporate management team. |
Celcuity Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Provide Ibrance(R) (palbociclib) for Planned Phase 3 Clinical TrialMINNEAPOLIS, MN / ACCESSWIRE / November 15, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, today announced that it has entered into a clinical trial collaboration and supply agreement with Pfizer to provide Ibrance® (palbociclib) for use in Celcuity's Phase 3 clinical trial at no cost to Celcuity. |
Celcuity to Participate in Upcoming Jefferies and Craig-Hallum Investor ConferencesMINNEAPOLIS, MN / ACCESSWIRE / November 9, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, today announced that Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, will participate in virtual meetings with investors at the following conferences: * 12th Annual Craig-Hallum Alpha Select Conference on November 16, 2021; and * Jefferies London |
Celcuity Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate UpdatePTMINNEAPOLIS, MN / ACCESSWIRE / November 8, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, today announced financial results for the third quarter ended September 30, 2021 and summarized recent business progress. |
Celcuity Inc. Schedules Release of Third Quarter 2021 Financial Results and Webcast/Conference CallMINNEAPOLIS, MN / ACCESSWIRE / October 29, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, today announced that it will release its financial results for the third quarter 2021 after the stock market close on Monday, November 8, 2021. |
CELC Price Returns
| 1-mo | -21.88% |
| 3-mo | -33.16% |
| 6-mo | -43.85% |
| 1-year | 51.76% |
| 3-year | -43.87% |
| 5-year | N/A |
| YTD | 64.85% |
| 2020 | -13.91% |
| 2019 | -55.65% |
| 2018 | 26.60% |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...